头颈部鳞状细胞癌的免疫检查点抑制剂：现状与未来方向。
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
机构信息
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
Department of Medical Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan.
出版信息
Head Neck. 2019 Oct;41 Suppl 1:4-18. doi: 10.1002/hed.25930.
BACKGROUND
Immune checkpoint inhibitors (ICIs) can reinvigorate T cells and activate the immune system to eliminate cancer cells. Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis. The roles of ICIs for HNSCC treatments are emerging.
METHOD
We reviewed the study results of Programmed-Death 1 (PD-1) and PD-ligand-1 (PD-L1) monoclonal antibodies for HNSCC. The ongoing trials of anti-PD-1 and anti-PD-L1 were also reviewed.
RESULTS
Nivolumab showed a significant overall survival benefit in platinum-refractory HNSCC patients. For platinum-sensitive or first-line patients, pembrolizumab monotherapy (patients with PD-L1 Combined Positive Score ≥ 20) or pembrolizumab-platinum-fluorouracil improved overall survival vs the EXTREME (cetuximab-platinum-fluorouracil). Many HNSCC studies have combined anti-PD1/PD-L1 therapy with various anticancer agents or radiotherapy to improve treatment efficacy.
CONCLUSION
ICIs demonstrate their efficacies for R/M HNSCC patients. The incorporation of ICIs showed a great impact on the treatment landscape of HNSCC.
背景
免疫检查点抑制剂（ICIs）可以重振 T 细胞并激活免疫系统以消除癌细胞。头颈部鳞状细胞癌（HNSCC）是一种预后不良的恶性肿瘤。ICI 用于 HNSCC 治疗的作用正在显现。
方法
我们回顾了 PD-1 和 PD-L1 单克隆抗体用于 HNSCC 的研究结果。还回顾了正在进行的抗 PD-1 和抗 PD-L1 试验。
结果
纳武利尤单抗在铂类难治性 HNSCC 患者中显示出显著的总生存获益。对于铂类敏感或一线患者，与 EXTREME 相比（西妥昔单抗-铂类-氟尿嘧啶），pembrolizumab 单药治疗（PD-L1 联合阳性评分≥20 的患者）或 pembrolizumab-铂类-氟尿嘧啶改善了总生存。许多 HNSCC 研究已经将抗 PD1/PD-L1 疗法与各种抗癌药物或放疗相结合，以提高治疗效果。
结论
ICI 对头颈部复发/转移（R/M）患者显示出疗效。ICI 的纳入对 HNSCC 的治疗格局产生了重大影响。
Zotero 插件